Rates of guideline-directed medical therapy for HF also differed across the trials, notably the use of sodium glucose co-transporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs). Here, NR3C2 is linked to hydrops fetalis.